Biological kits
Ended Awarded Last action
- Contract number
- 75N91025F00025
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $238,378
Award facts
- Contract value 100% obligated
- $238,377.83 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $238,378 |
About this award
Illumina, Inc., a leading biotechnology company headquartered in San Diego, California, was awarded a delivery order contract by the National Cancer Institute (NCI) on June 26, 2025, with a ceiling value of $238,377.83 for the delivery of biological kits. This firm fixed price contract, with an ultimate completion date of June 25, 2026, will be performed at Illumina's San Diego facility and represents no set-aside designation. As a specialized provider of genetic sequencing and genomic analysis technologies, Illumina supplies the NCI with advanced DNA and RNA sequencing instruments, reagent kits, and related consumables that support critical cancer research and diagnostic initiatives.
This delivery order award reflects Illumina's established track record as a primary supplier of genomic sequencing solutions across multiple federal civilian agencies, including the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. The contract aligns with the NCI's mission to support cancer research through cutting-edge molecular and genetic analysis capabilities. Illumina's specialized technological expertise and proven capabilities in genomic sequencing technologies, combined with the absence of a set-aside designation, underscore the contractor's competitive positioning as the appropriate source for delivering these specialized biological kits to the agency.
Quick answers
Who was awarded contract 75N91025F00025?
75N91025F00025 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on June 26, 2025.
How much is contract 75N91025F00025 worth?
The government has obligated $238,378 on 75N91025F00025.
Is contract 75N91025F00025 an order under another contract?
Yes. 75N91025F00025 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N91025F00025 competed?
The extent of competition for 75N91025F00025 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award